Binge Eating DisorderPhase 2BEDNCT01291173
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
A Phase 2 study testing lisdexamfetamine dimesylate (SPD489) in people with Binge Eating Disorder, run by Shire at 31 sites in United States.
Trial summary
To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Binge Eating Disorder
- What is being tested?
- lisdexamfetamine dimesylate (SPD489)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 271 participants
- Where
- 31 sitesUnited States
- Study dates
- 10 May 2011to 30 Jan 2012
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Subject meets the following Diagnostic and Statistical Manual of Mental Disorders Fourth Edition - Text Revision (DSM-IV-TR) criteria for a diagnosis of binge eating disorder (BED).
- Binge eating disorder is of at least moderate severity in which subjects report at least 3 binge eating days per week.
- Subject has a body mass index (BMI) of >24 and <46.
Who cannot join
- Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.
- Subject is considered a suicide risk or risk to harm others.
Trial locations and contacts
31 sites in 1 country.
31 sites in 1 country
United States31 sites
Atlanta Institute of Medicine and Research
Atlanta, Georgia, 30328
FutureSearch Clinical Trials
Austin, Texas, 78731
McLean Hospital
Belmont, Massachusetts, 02478
Southwestern Research, Inc.
Beverly Hills, California, 90210
Boston Clinical Trials
Boston, Massachusetts, 02135
Florida Clinical Research
Bradenton, Florida, 32408
Weight Management Center, Medical University of South Carolina
Charleston, South Carolina, 29425
Charlottesville Medical Research
Charlottesville, Virginia, 22911
Community Research
Cincinnati, Ohio, 45227
Neuropsychiatric Research Institute
Fargo, North Dakota, 58103
Gulfcoast Clinical Research
Fort Myers, Florida, 33912
Drug Development, Inc.
Houston, Texas, 77081
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, 32216
Scripps Clinical Research Services
La Jolla, California, 92037
Robert Lynn Horne, MD
Las Vegas, Nevada, 89102
Capstone Clinical Research
Libertyville, Illinois, 60048
Clinical Study Centers, LLC
Little Rock, Arkansas, 72205
Lindner City of Hope
Mason, Ohio, 45040
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, 38119
Unniversity of Minnesota
Minneapolis, Minnesota, 55454
Louisiana Research Associates, Inc.
New Orleans, Louisiana, 70114
Pharmacology Research Institute
Newport Beach, California, 92660
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, 32806
Vince and Assoc. Research
Overland Park, Kansas, 66212
Clinical Trials Technology, Inc.
Prairie Village, Kansas, 66206
Wake Research Associates
Raleigh, North Carolina, 27612
Marc Hertzman, MD, PC
Rockville, Maryland, 20852
PCSD - Feighner Research
San Diego, California, 92108
Carman Research
Smyrna, Georgia, 30080
Weight Disorders Washington University School of Medicine, Dept of Psychiatry
St Louis, Missouri, 63110
Richmond Behavioral Associates
Staten Island, New York, 10312
About this study
Official title: A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder
To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
- Conditions
- Binge Eating Disorder
- Being tested
- lisdexamfetamine dimesylate (SPD489), Placebo
- Medical subject headings
- Binge-Eating Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
lisdexamfetamine dimesylate (SPD489)Drug
Also called LDX, Vyvanse
SPD489-30mg capsules taken once daily for up to 11 weeks
lisdexamfetamine dimesylate (SPD489)Drug
Also called LDX, Vyvanse
SPD489 50mg capsules taken once-daily for up to 11 weeks
lisdexamfetamine dimesylate (SPD489)Drug
Also called LDX, Vyvanse
SPD489 70mg capsule taken once-daily for up to 11 weeks
PlaceboDrug
Placebo capsule taken once daily for up to 11 weeks
| Study group | Role | What they receive |
|---|---|---|
| SPD489 30 mg | Experimental | Not described Receives: Drug: lisdexamfetamine dimesylate (SPD489) |
| SPD489 50 mg | Experimental | Not described Receives: Drug: lisdexamfetamine dimesylate (SPD489) |
| SPD489 70 mg | Experimental | Not described Receives: Drug: lisdexamfetamine dimesylate (SPD489) |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Log Transformed Binge Days Per Week at Week 11
Binge day is defined as a day during which at least 1 binge episode occurs.
Measured: Baseline and week 11
Secondary outcomes (13)
Change From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks
The number of binge episodes per week as assessed by clinical interview based on subject diary.
Measured: Baseline and up to 11 weeks
1-Week Binge Response, Last Observation Carried Forward (LOCF)
The 1-week binge response was defined as either a 1-week remission (a 100% reduction of binge episodes from baseline [ie, a cessation of binge eating behavior]), or a marked response (75 to <100% reduction in binge episodes from baseline), or a moderate response (50 to <75% reduction in binge episodes from baseline), or a negative/minimal response (<50% reduction in binge episodes from baseline). The 1-week response was determined at the end of the study utilizing a LOCF approach.
Measured: Last 7 days on study
4-Week Binge Response
Subjects are free from binge episodes for 4 weeks.
Measured: Last 28 days on study
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Measured: Baseline
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Up to 11 Weeks
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Measured: up to 11 weeks
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Measured: Up to 11 weeks
Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11
The YBOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. A score of 0-7 is sub-clinical; 8-15 is mild; 16-23 is moderate; 24-31 is severe; and 32-40 is extreme.
Measured: Baseline and week 11
Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Measured: Baseline and week 11
Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11
The HAM-A is a rating scale developed to quantify the severity of anxiety symptomatology. It consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe) with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe, and 31-56 severe anxiety.
Measured: Baseline and week 11
Change From Baseline in Eating Inventory Score at Week 11
The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior: cognitive restraint of eating, disinhibition, and hunger. Cognitive restraint of eating consists of 20 items, disinhibition consists of 16 items, and hunger consists of 15 items. Each item scores either 0 or 1 point for a total score of 0-20 for cognitive restraint of eating, 0-16 for disinhibition, and 0-15 for hunger. A higher score is better for cognitive restraint of eating and lower scores are better for disinhibition and hunger.
Measured: Baseline and week 11
Change From Baseline in Binge Eating Scale (BES) Score at Week 11
The BES is a 16-item self-reported questionnaire that is designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. The items are summed, with possible scores ranging from 0 to 46. A score of 27 or higher indicates severe binge-eating problems, and a score of 17 or lower designates no binge-eating problems.
Measured: Baseline and week 11
Change From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11
The BIS-11 is a self-reported 30-item questionnaire that measures impulsiveness using a 4-point Likert scale (rarely/never = 1, occasionally = 2, often = 3, almost always/always = 4). A Total Impulsivity score is calculated by summing the scores for each item. Possible scores range from 30 - 120. Higher scores indicate increased impulsiveness.
Measured: Baseline and week 11
Change From Baseline in Short Form-12 Health Survey (SF-12) Score at Week 11
The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. There are 8 subscales. Four of the subscales has one-item each; the other 4 have two-items each. For each subscale, a mean value was first computed and transformed to a position on a scale ranging from 0-100 (Z-transformation). The aggregate total scores are then transformed into a mean value ranging from 0 (lowest level of health) to 100 (highest level of health).
Measured: Baseline and week 11
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Feb 2011 (estimated)
- Study start10 May 2011
- Primary completion30 Jan 2012
- Study completion30 Jan 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Binge Eating DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 271 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shire
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Study Director, Study director, Takeda
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01291173
- Sponsor's protocol ID
- SPD489-208
- Acronym
- BED
- Status last verified
- May 2021
- First submitted
- 4 Feb 2011
- Last updated
- 10 Jun 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, Wang J, Whitaker T, Jonas J, Gasior M. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015 Mar;72(3):235-46. doi: 10.1001/jamapsychiatry.2014.2162.
PubMed 25587645
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder
- ClinicalTrials.gov ID
- NCT01291173
- Acronym / sponsor ID
- BED / SPD489-208
- Conditions
- Binge Eating Disorder
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 271 participants (actual)
- Lead sponsor
- ShireIndustry (pharma, biotech, devices)
- Study start
- 10 May 2011 (actual)
- Primary completion
- 30 Jan 2012 (actual)
- Study completion
- 30 Jan 2012 (actual)
- First posted
- 8 Feb 2011 (estimated)
- Results
- Posted 31 Dec 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| SPD489 30 mg | Experimental | Drug: lisdexamfetamine dimesylate (SPD489) |
| SPD489 50 mg | Experimental | Drug: lisdexamfetamine dimesylate (SPD489) |
| SPD489 70 mg | Experimental | Drug: lisdexamfetamine dimesylate (SPD489) |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Subject meets the following Diagnostic and Statistical Manual of Mental Disorders Fourth Edition - Text Revision (DSM-IV-TR) criteria for a diagnosis of binge eating disorder (BED).
- Binge eating disorder is of at least moderate severity in which subjects report at least 3 binge eating days per week.
- Subject has a body mass index (BMI) of >24 and <46.
Key exclusion criteria (2 listed)
- Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.
- Subject is considered a suicide risk or risk to harm others.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| lisdexamfetamine dimesylate (SPD489)Also: LDX, VyvanseSPD489-30mg capsules taken once daily for up to 11 weeks | Drug | SPD489 30 mg |
| lisdexamfetamine dimesylate (SPD489)Also: LDX, VyvanseSPD489 50mg capsules taken once-daily for up to 11 weeks | Drug | SPD489 50 mg |
| lisdexamfetamine dimesylate (SPD489)Also: LDX, VyvanseSPD489 70mg capsule taken once-daily for up to 11 weeks | Drug | SPD489 70 mg |
| PlaceboPlacebo capsule taken once daily for up to 11 weeks | Drug | Placebo |
Primary outcome
Change From Baseline in Log Transformed Binge Days Per Week at Week 11
Time frame: Baseline and week 11
Binge day is defined as a day during which at least 1 binge episode occurs.
13 secondary outcomes
Change From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks
Time frame: Baseline and up to 11 weeks
1-Week Binge Response, Last Observation Carried Forward (LOCF)
Time frame: Last 7 days on study
4-Week Binge Response
Time frame: Last 28 days on study
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline
Time frame: Baseline
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Up to 11 Weeks
Time frame: up to 11 weeks
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks
Time frame: Up to 11 weeks
Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11
Time frame: Baseline and week 11
Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11
Time frame: Baseline and week 11
Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11
Time frame: Baseline and week 11
Change From Baseline in Eating Inventory Score at Week 11
Time frame: Baseline and week 11
Change From Baseline in Binge Eating Scale (BES) Score at Week 11
Time frame: Baseline and week 11
Change From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11
Time frame: Baseline and week 11
Change From Baseline in Short Form-12 Health Survey (SF-12) Score at Week 11
Time frame: Baseline and week 11
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 25587645McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, Wang J, Whitaker T, Jonas J, Gasior M. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015 Mar;72(3):235-46. doi: 10.1001/jamapsychiatry.2014.2162.
Related trials for Binge Eating Disorder
Not yet recruiting
Be Body Brave: Digital Written Exposure Therapy for Eating Disorders
Eating Disorders
Enrolling by invitationPhase 3
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder
Binge-Eating Disorder
Not yet recruiting
Effectiveness of a 10-week Multicomponent Intervention Combined With Parent Education on Binge Eating Behavior in Children and Adolescents
Binge Eating Disorder, Binge Eating
Enrolling by invitation
Sleep and Activity For Eating Disorders
Eating Disorders, Anorexia Nervosa
Active, not recruiting
Project VIBE: Virtual Intervention for Binge Eating in Adolescents
Obesity, Binge-Eating Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Study Director study director
Takeda
31 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing lisdexamfetamine dimesylate (SPD489) in people with Binge Eating Disorder, run by Shire at 31 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 31 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 31 Dec 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Log Transformed Binge Days Per Week at Week 11 (time frame: Baseline and week 11). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01291173, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2021.